Contact Us

Roche: Information platform empowers the public with knowledge on latest cancer treatment technologies According to data from the Hong Kong Cancer Registry of the Hospital Authority, the overall five-year survival rate for cancer patients has...

Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson’s disease Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody,...

Artera: Clinicians and patients throughout New York State can now access personalized, actionable insights to inform prostate cancer treatment decisions SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal...